Table 3.
Univariate analysis of biochemical progression-free survival
| Parameter |
8-year bPFS [%] (95%CI) |
p |
|---|---|---|
| PSA |
|
0.41 |
| ≤ 15 ng/ml |
66.6 (44.3–88.9) |
|
| >15 ng/ml |
75.1 (64.9–85.3) |
|
| ADT |
|
0.22 |
| no |
|
|
| |
66.7 (51.2–82.2) |
|
| yes |
78.4 |
|
| |
(67.0–89.8) |
|
| Dose (prostate) |
|
0.78 |
| ≤ 74 Gy |
76.7 (64.9–88.5) |
|
| >74 Gy |
68.8 (53.5–84.1) |
|
| Gleason |
|
0.50 |
| < 7 |
75.4 (63.4–75.4) |
|
| ≥ 7 |
72.0 (56.9–87.1) |
|
| Risk category |
|
0.58 |
| Intermediate-risk |
76.4 (63.3–89.5) |
|
| High-risk |
70.9 (57.8–84.0) |
|
| Age |
|
0.13 |
| ≤ 61 years |
70.1 |
|
| |
(59.7–80.5) |
|
| > 61 years |
88.9 |
|
| |
(68.3–100.0) |
|
| HIF1α |
|
0.019 |
| ≤ 50% |
64.6 (43.0–86.2) |
|
| >50% |
75.5 (65.1–85.9) |
|
| EGFR |
|
0.05 |
| strong |
61.6 (41.8–81.4) |
|
| weak |
65.1 (48.0–82.2) |
|
| negative |
85.0 (71.9–98.1) |
|
| VEGF-A |
|
0.92 |
| l ow |
70.5 (51.7–89.3) |
|
| high | 74.4 (63.6–85.2) |
PSA prostatic-specific antigen, ADT anti-androgen deprivation therapy.